Teva Faces Turkish Antitrust Probe Over Patent Practices — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Turkey's Competition Board (Rekabet Kurumu) launched an antitrust probe into Teva for allegedly manipulating the patent system and making misleading statements to health authorities about rival drugs' safety and effectiveness.
- The board disclosed the decision last Friday on its website, saying Teva engaged in practices "aimed at making it more difficult for competitors to enter the market."
- The regulator did not name a specific drug tied to the Turkish investigation.
- Teva spokesperson said the Turkish probe resembles a European Commission investigation from two years ago that ended with the company paying a $503 million fine for delaying competition to its blockbuster Copaxone multiple sclerosis medicine.
- The European Commission case is currently under appeal before the European Court.
Why it matters: Teva already paid $503 million to resolve a similar EU case involving Copaxone, which remains under appeal — so a second major jurisdiction pursuing comparable allegations compounds the legal and financial exposure for the world's largest generic drugmaker and signals that the alleged Copaxone-style tactics are drawing renewed scrutiny abroad.
Ask SkimNews
